



To whom it may concern

December 6, 2021

Company name: SEIKOH GIKEN Co., Ltd.

Name of representative: Masatoshi Ueno, President and Chief Executive Officer

(Code No. 6834, Tokyo Stock Exchange JASDAQ)

Inquiries to: Yuji Saitoh, Executive Director, Administration Department Manager

(TEL. +81-47-388-6401)

Notification of Commencement of Mass Production of Microfluidic Devices for Medical Use


Seikoh Giken is pleased to announce that we have established a production line for the manufacture of microfluidic devices for medical use, and have started mass production.

To date we have developed molds for the mass production of CDs and DVDs, which we have provided to optical disc makers around the world. The inner surfaces of optical discs feature countless indentations several micrometers in diameter called "pits," which are used to record information. Advanced mold technology is indispensable in mass producing and molding optical discs in cycles of two or three seconds while accurately capturing the minute pits of each disc.

Utilizing molding technology with the highest level of precision in the industry, achieved through the development of the optical disc molds for which we hold the top position in the world market, we have established a new mass production line for plastic microfluidic devices for medical use in the number four clean room at our factory in Matsudo City, Chiba Prefecture.

Microfluidic devices for medical use have microscopic channels on their surfaces through which specimens and reagents are mixed, and at present are usually made from glass. We have successfully utilized molding techniques and precision molding technology to mass-produce microfluidic devices made of resin, which is easier to mass-produce than glass. The surfaces of these devices have minute channels of less than 10 micrometers deep and wide, and the entire process from molding to film bonding is carried out automatically in the clean room. Going forward we will steadily increase the number of production lines, and plan to increase production to a level of 100,000 units per month by the fiscal year ending March 2024. Microfluidic devices can be used in a variety of tests, and we anticipate that they will be used in tests for lifestyle-related illnesses and influenza testing, as well as PCR tests for COVID-19, for which demand is

now growing. Initially, we plan to provide them mainly to makers of medical devices and biotechnology, and are also considering future expansion overseas.



◆ "Microfluidic devices for medical use"

End